AGIO
Agios Pharmaceuticals, Inc.
Biotechnology · Healthcare · United States
30.55
close · 2026-10-30
value
46
cheaper than peers46
quality
86
stronger fundamentals86
ranked against
Biotechnology (commercial)
value
quality
162 peerswide variation
Value inputs
| measure | company | vs peers |
| earnings yield, 1 year ago | 38.1% | 100 |
| price to book | 1.77× | 75 |
| earnings yield, 3 years ago | -13.8% | 53 |
| earnings yield, 2 years ago | -20.7% | 46 |
| price to sales | 18.55× | 38 |
| earnings yield, latest year | -23.3% | 38 |
| cash flow yield, 2 years ago | -17.2% | 35 |
| cash flow yield, 3 years ago | -17.2% | 33 |
| cash flow yield, latest year | -21.2% | 33 |
| cash flow yield, 1 year ago | -21.5% | 31 |
10 of 12 measures available
Quality inputs
| measure | company | vs peers |
| revenue growth | 259.3% | 87 |
| debt to equity | 3.0% | 80 |
| return on equity | -34.3% | 65 |
| operating margin | -247.1% | 43 |
4 of 4 measures available
Facts
| market cap | $2B |
| free cash flow | -$274.6M |
| employees | 539 |
| first trade | 2013-07-24 |
| next earnings | 2026-11-05 |
| fundamentals updated | 2026-08-05 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -7.12 | 11.64 | -6.33 | -4.23 |
| free cash flow | -$387.3M | -$391.5M | -$314.6M | -$314.4M |
| net income | -$412.8M | $673.7M | -$352.1M | -$231.8M |
| revenue | $54.0M | $36.5M | $26.8M | $14.2M |
| unusual items | $0 | $1.09B | $0 | $137.7M |